Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population

Marjan Kerkhof,1 Trung N Tran,2 Joan B Soriano,3 Sarowar Golam,4 Danny Gibson,5 Elizabeth V Hillyer,1 David B Price1,6

ABSTRACT
Background Little is known about the prevalence of severe, uncontrolled eosinophilic asthma (SUEA) and associated costs.
Aims We sought to determine the prevalence of SUEA and compare asthma-related healthcare resource use (HCRU) and associated costs with overall means for a general asthma population.
Methods This cohort study evaluated anonymised medical record data (December 1989 through June 2015) from the Clinical Practice Research Datalink and the Optimum Patient Care Research Database to study UK patients with active asthma (diagnostic code and one or more drug prescriptions in the baseline year), aged 5 years and older, without concomitant COPD, and with recorded eosinophil count. SUEA was defined as two or more asthma attacks during 1 baseline year preceding a high blood eosinophil count (≥0.3×10^9/L) for patients prescribed long-acting β2-agonist (LABA) and high-dosage inhaled corticosteroids (ICS) during baseline plus 1 follow-up year. We compared asthma-related HCRU and associated direct costs (2015 pounds sterling, £) during the follow-up year for SUEA versus the general asthma population.
Results Of 363,558 patients with active asthma and recorded eosinophil count, 64% were women, mean (SD) age was 49 (21) years; 43% had high eosinophil counts, 7% had two or more attacks in the baseline year and 10% were prescribed high-dosage ICS/LABA for 2 study years. Overall, 2940 (0.81%; 95% CI 0.78% to 0.84%) patients had SUEA. Total mean per-patient HCRU and associated costs were four times greater for SUEA versus all patients (HCRU and cost ratios 3.9; 95% CI 3.7 to 4.1).
Conclusions Less than 1% of patients in a general asthma population had SUEA. These patients accounted for substantially greater asthma-related HCRU and costs than average patients with asthma.

INTRODUCTION
Asthma currently affects an estimated 358 million individuals worldwide, posing a substantial burden on healthcare systems.1 While most asthma can be controlled with available therapies, some patients experience symptoms and severe asthma attacks even with high-intensity therapy (ie, Global Initiative for Asthma (GINA) Step 4/5 therapy with high-dosage inhaled corticosteroids (ICS) plus another controller medication and/or systemic corticosteroids). These patients with severe uncontrolled asthma comprised 2.3%–3.6% of patients with persistent asthma in recent population-based studies using administrative and prescribing databases.3 4 Uncontrolled asthma accounts for a disproportionate share of asthma-related healthcare resource use (HCRU) and costs.5 6 Eosinophilic asthma is a common phenotype of severe asthma,7–10 and patients with eosinophilic asthma are at heightened risk of asthma attacks.11–15 Biological agents mepolizumab and reslizumab that target the interleukin-5 molecule directly to reduce eosinophils have been demonstrated to reduce asthma attacks and improve symptoms in patients with severe, uncontrolled eosinophilic asthma (SUEA), with the potential to reduce patient exposure to high dosages of ICS and oral corticosteroids (OCS) and related adverse effects.16–19 Bezlizuimab targets the interleukin-5 receptor α and induces direct, rapid and nearly complete depletion of eosinophils. In the phase III SIROCCO and CALIMA trials, bezlizuimab significantly reduced exacerbations, increased lung function and improved asthma symptoms for patients with severe, uncontrolled asthma with eosinophilic
inflammation. While benralizumab is effective across the full spectrum of patients studied, the best responses to these agents are associated with greater eosinophil counts and asthma attack rates. Therefore, information is needed on the prevalence of asthma and associated HCRU to understand the patient population for which the use of these medications is justified.

Administrative and electronic databases afford the opportunity to study large numbers of patients. In the UK, anonymised databases are available that draw on centralised electronic medical records housed at primary care practices. The aims of this historical follow-up study were to determine the population burden of asthma and to estimate the asthma-related HCRU and associated costs. Our first objective was to describe the distribution of asthma severity and control, treatment status, high blood eosinophil count and their combinations and to establish the proportion of patients with SUEA in the general UK general population. Our second objective was to determine the asthma-related HCRU and associated costs for SUEA as compared with those for a general asthma population.

**METHODS**

**Data source**

This historical follow-up study was performed using datasets extracted from the Clinical Practice Research Datalink (CPRD) and the Optimum Patient Care Research Database (OPCRD), which contain anonymised, longitudinal medical record data from >650 and 500 UK primary care practices, respectively, for patients from throughout the UK. The data include information from general practice (GP) visits as well as secondary care and hospital attendances. The CPRD, formerly known as the General Practice Research Database (GPRD), is a well-maintained and well-regarded database that has been used for public health research since 1987. The OPCRD is a bespoke database designed for use in clinical and epidemiological research.

Two datasets were constructed separately using CPRD and OPCRD data in a patient unidentifiable form with harmonised variables. The datasets were checked for overlapping data to exclude any duplicate data (details in online supplementary material). The CPRD dataset contained patient records from June 1994 through January 2015 and was linked for a percentage of patients to Hospital Episode Statistics (HES), a data warehouse containing more complete and reliable information on inpatient hospital admissions. The OPCRD dataset contained patient records from December 1989 through June 2015.

The study was performed in compliance with all applicable local and national laws and regulations, including approvals for dataset use and the study protocol, and in accordance with standards suggested for observational studies (see online supplementary material).

**Study design and patients**

Patients eligible for inclusion in this study were ≥5 years old at the time of their most recent asthma diagnoses, recorded as a diagnostic Read code for asthma qualifying for inclusion in the register of patients with asthma, which general practices in the UK maintain for the Quality Outcomes Framework (QOF). In addition, eligible patients had at least one valid blood eosinophil count after their asthma diagnoses and ≥2 years of continuous data used for this study, including ≥1 year (baseline year for patient characterisation) before their last recorded eosinophil count, and ≥1 year after the eosinophil count (outcome year). The date of the last recorded blood eosinophil count was defined as the index date, and eligible patients had to have received at least one prescription for asthma during the baseline year. Patients with asthma and no concomitant diagnosis of chronic obstructive pulmonary disease (COPD) constituted the main study population; and patients ≥40 years with both asthma and COPD diagnoses were assessed in separate analyses. Patients with a diagnostic Read code for chronic lower respiratory conditions other than asthma or COPD, such as bronchiolitis obliterans or cystic fibrosis, were excluded from the study.

**Study measures and definitions**

We defined *severe asthma* as combination maintenance therapy with high-dosage ICS and long-acting β2-agonist (LABA) in both the baseline and the outcome years, *uncontrolled asthma* as two or more asthma attacks in the baseline year, and *eosinophilic asthma* as a blood eosinophil count of ≥0.3×10^7/L at index date. We defined patients as having SUEA if they were receiving high-dosage ICS plus LABA in both baseline and outcome years, had two or more attacks in the baseline year and had a high blood eosinophil count of ≥0.3×10^7/L at index date.

The three components of the composite definition of SUEA were based on several sources. The definition of severe asthma was based on the definition of high-dosage ICS in the 2014 British guideline on the management of asthma, namely as a cumulative chlorofluorocarbon beclomethasone dipropionate (BDP)–equivalent dosage of ≥800 µg/day for adults and ≥400 µg/day for children 5–12 years. We calculated the ICS daily dosage separately for the baseline and outcome years using the cumulative ICS exposure based on all prescriptions for each year (see online supplementary material). Asthma attacks were defined, according to the consensus European Respiratory Society/American Thoracic Society task force definition of severe asthma exacerbations, as the occurrence of any of the following events: respiratory-related hospital attendance or admission, emergency department (ED) attendance or acute OCS course. A blood eosinophil count of ≥0.3×10^7/L was chosen as reported to be optimal for predicting sputum eosinophilia of ≥3%, reflecting airway eosinophilia.

Risk-domain asthma control was defined as the absence of asthma attacks and no antibiotic prescribed with evidence of a lower respiratory consultation. Overall asthma control was defined as attainment of risk-domain asthma control plus a mean daily dosage of ≤200 µg salbutamol (or ≤500 µg terbutaline).

We determined asthma treatment step according to the GINA guidelines using the highest step during the baseline year, with the daily dosage of ICS based on the last prescription before the index date (see online supplementary material).

We assessed asthma-related HCRU, including medications, asthma-related GP and hospital-based specialist clinic visits, hospitalisations and lower respiratory-related ED visits during the outcome year. With regard to HCRU that occurred on the index date, we assessed HCRU events (eg, GP visits or hospitalisations) as being part of the baseline year, because exacerbations, for example, might have been a reason for doing a full blood count (including eosinophil count), which defined the index date. Instead, medications prescribed on the index date were included in the outcome year tallies as treatment during the outcome period. Asthma-related direct costs during the outcome year were determined using standard unit costs for the UK National Health Service for 2015 (see online supplementary material).

**Statistical analyses**

We used summary statistics to describe the distribution of asthma severity and control, treatment status, high blood eosinophil
counts, other asthma determinants and their combinations in the baseline year before the index date, and we described mean asthma-related HCRU and associated direct costs during the outcome year. Although the distributions were skewed, we reported the means for HCRU, costs and cost ratios as recommended.12–14 The means can be multiplied by a target population to estimate total costs and are therefore of most use to policy-makers and providers. We performed the analyses separately for patients with and without a concomitant diagnosis of COPD. Analyses for those with concomitant COPD included only patients aged ≥40 years, described in the online supplementary material.

The mean numbers of HCRU events per patient during the outcome year were calculated with SDs. The means were then multiplied by unit costs for the cost year 2015 (expressed as pounds sterling, £) to provide mean (SD) annual, asthma-related healthcare costs for individuals (details in online supplementary material). The HCRU and cost analyses requiring information about inpatient hospitalisations were performed for the subgroup of patients in the CPRD dataset who had linked HES data. Sensitivity analyses on HCRU and costs were performed using different definitions of SUEA based on three additional definitions of high eosinophil count, namely ≥0.2×10^9/L, ≥0.4×10^9/L and ≥0.5×10^9/L. The HCRU and costs were described also for patients with prescriptions for maintenance oral corticosteroids. Cost ratios were estimated by calculating the ratios of the mean costs for the subgroup of patients with SUEA to those for the reference group of all patients with asthma. All 95% CIs were estimated based on 1000 bootstrap replicates (see online supplementary material).

Analyses were performed using IBM SPSS Statistics V.23 (IBM SPSS Statistics, Feltham, Middlesex, UK) and R V.3.0.2 (The R Project for Statistical Computing; https://www.r-project.org/).

**RESULTS**

**Patient populations**

In the two databases, 1,016,696 of 2,117,427 patients (48%) with asthma diagnostic code had recorded eosinophil counts. Of these, we identified a total of 401,261 (39%) patients with active asthma who met all eligibility criteria (figure 1). The main study population (those without a concomitant COPD diagnosis) included 363,558 (91%) patients with active asthma who had index dates from 6 December 1990 to 23 June 2014, with a median (IQR) index date year of 2011 (2008–2012); 0.7% of patients had an index date before the year 2000. Our findings concerned two or more attacks during the baseline year. Of the 6326 patients who received high-dosage ICS plus LABA during both baseline and outcome years; and 6326 (1.7%) received high-dosage ICS plus LABA during both baseline and outcome years and also experienced two or more attacks during the baseline year. Of the 6326 patients, a total of 2940 patients (46.5%), or 0.81% (95% CI 0.78% to 0.84%) of the main study population, met the study definition of SUEA, namely high-dosage ICS plus LABA in both baseline and outcome years, two or more attacks in the baseline year and high blood eosinophil count of ≥0.3×10^9/L at the index date.

**Demographic and clinical characteristics and asthma burden**

In the main study population, 24,047 (7%) patients experienced two or more attacks during the baseline year; 34,898 (10%) received high-dosage ICS plus LABA during both baseline and outcome years; and 6326 (1.7%) received high-dosage ICS plus LABA during both baseline and outcome years and also experienced two or more attacks during the baseline year. Of the 6326 patients, a total of 2940 patients (46.5%), or 0.81% (95% CI 0.78% to 0.84%) of the main study population, met the study definition of SUEA, namely high-dosage ICS plus LABA in both baseline and outcome years, two or more attacks in the baseline year and high blood eosinophil count of ≥0.3×10^9/L at the index date.

Tables 1 and 2 summarise demographics and baseline clinical characteristics for all ages combined (≥5 years) and for adults (18–64 and ≥65 years) in the SUEA population and the main study population. The median (IQR) index date years were 2011 (2009–2013) for SUEA and 2011 (2008–2012) for the total population. Most patients with SUEA were ≥18 years. Only 57 patients (2%) were <18 years, including 14 children who were 5–11 years old and 43 who were 12–17 years old (online supplementary table S1). Overall, the SUEA population was older than the main study population—983 (33%) and 95189 (26%) were ≥65 years. Only 57 patients (2%) were <18 years, including 14 children who were 5–11 years old and 43 who were 12–17 years old (online supplementary table S1). Overall, the SUEA population was older than the main study population—983 (33%) and 95189 (26%) were ≥65 years, respectively—but included roughly the same proportion of female patients (1952 (66%) and 233210 (64%) female, respectively) (table 1). On the index date, blood eosinophil counts of ≥0.3×10^9/L were recorded for 156136 (43%) patients, including 91,865/233210 (39%) female patients and 64,271/130,348 (49%) male patients (table 2).

The 2940 patients in the SUEA population and those in each of the adult SUEA cohorts, compared with patients in the main study population, were less likely to have been normal weight, more likely to have been obese, and more likely to have had recorded comorbidities, with the greatest differences between SUEA and main populations overall in the recorded frequency of nasal polyps, followed by non-allergic rhinitis, chronic sinusitis, gastro-oesophageal reflux disease, cardiovascular...
Table 1  Demographics and baseline clinical characteristics of the main study population (including patients with SUEA) and the SUEA population:

| Variable                              | All patients (age ≥5 years)* | 18–64 years old | ≥65 years old |
|---------------------------------------|------------------------------|-----------------|---------------|
|                                       | All ages (n=3,635,558)       | All 18–64 years old (n=2,427,714) | All ≥65 years old (n=95,189) |
|                                       | SUEA (n=2,940)               | SUEA (n=1,900) | SUEA (n=983)  |
| Female sex, n (%)                     | 233,210 (64.1)              | 195,269 (66.4) | 61,990 (65.1) |
| Age at index date, mean (SD)          | 49.4 (20.6)                   | 43.0 (12.8)    | 75.5 (7.5) |
| Body mass index, n (%)                |                              |                 |              |
| Underweight                           | 10,152 (3.3)                 | 39,48 (1.9)     | 1642 (1.9)   |
| Normal                                | 96,309 (31.0)                | 6,852 (30.7)    | 24,984 (29.0) |
| Overweight                            | 100,937 (32.4)               | 67,176 (31.8)   | 32,116 (37.3) |
| Obese                                 | 103,738 (33.3)               | 75,319 (35.6)   | 27,470 (31.9) |
| Unknown, n                            | 52,422                       | 31,419          | 8,977        |
| Smoking status, n (%)                |                              |                 |              |
| Current smoker                        | 64,350 (18.0)                | 56,194 (23.4)   | 6,218 (6.6)  |
| Ex-smoker                             | 93,359 (26.2)                | 56,807 (23.7)   | 35,941 (38.2) |
| Never smokers                         | 199,299 (55.8)               | 126,664 (52.9)  | 51,906 (55.2) |
| Unknown, n                            | 6550                         | 31,419          | 8,977        |
| Charlson comorbidity index, n (%)    |                              |                 |              |
| 0                                     | 166,280 (45.7)               | 118,122 (48.7)  | 35,111 (36.9) |
| 1–4                                   | 170,791 (47.0)               | 114,735 (47.3)  | 43,500 (45.7) |
| ≥5                                    | 26,487 (7.3)                 | 9857 (4.1)      | 16,578 (17.4) |
| Ever-recorded comorbidity, n (%)     |                              |                 |              |
| Eczema                                | 105,659 (29.1)               | 68,507 (28.2)   | 25,188 (26.5) |
| Allergic rhinitis                     | 62,490 (17.2)                | 45,790 (18.9)   | 12,789 (13.4) |
| Non-allergic rhinitis                 | 32,285 (8.9)                 | 19,918 (8.2)    | 10,825 (11.4) |
| Chronic sinusitis                     | 35,708 (9.8)                 | 24,940 (10.3)   | 10,351 (10.9) |
| Nasal polyps                          | 12,949 (3.6)                 | 7,070 (2.9)     | 5,802 (6.1)  |
| Gastro-oesophageal reflux disease     | 42,154 (11.6)                | 25,129 (10.4)   | 16,323 (17.1) |
| Cardiovascular disease                | 93,443 (25.7)                | 44,393 (18.3)   | 48,411 (50.9) |

*All patients with SUEA included children who were 5–11 years old and 43 adolescent patients 12–17 years old.
†The percentages for BMI and for smoking status were calculated for patients with available data. Overall, patients with missing data for BMI represented 14% of patients and for smoking status, 2% of patients. The BMI categories, determined from data closest to the index date, were defined as follows: underweight, <18.5 kg/m²; normal weight, ≥18.5 kg/m² to <25 kg/m²; overweight, ≥25 kg/m² to <30 kg/m²; and obese, ≥30 kg/m².

Demographics and baseline clinical characteristics of patients with SUEA defined using different definitions of high blood eosinophil count are described in online supplementary table S2. The prevalence ranged from 1.2% at an eosinophil count of ≥0.2×10⁹/L to 0.3% at a count of ≥0.5×10⁹/L.

Healthcare resource use and costs

The mean HCRU and direct, asthma-related costs for each HCRU-related category were from 2.5 to 7.6 times greater for the SUEA cohort than for the main study population with active asthma, as summarised in table 3. The mean number of GP visits was 2.7 for the SUEA cohort and 1.4 for the main population, and the mean numbers of hospital-based specialist visits were 0.30 versus 0.04, respectively. During the outcome year, 627 of the 2940 patients in the SUEA cohort (21.3%) experienced two asthma attacks, and 387 (13.2%) and 393 (13.4%) experienced three and four or more attacks, respectively. Corresponding numbers for the main population of 363,558 patients with active asthma were 13,556 (3.7%), 5165 (1.4%) and 2987 (0.8%), respectively (online supplementary table S3).

The total mean asthma-related costs were £861 for the SUEA cohort versus £222 for the main study population, for a cost ratio of 3.9 (95% CI 3.7 to 4.1). The asthma-related HCRU and associated cost ratios for patients with SUEA appeared to increase with the increasing blood eosinophil counts used to
## Asthma

### Table 2  Clinical characteristics and asthma disease burden of the main study population (including patients with SUEA) and the SUEA population: all ages (≥5 years) and the adult cohorts

| Variable | All patients (age ≥5 years)* | 18–64 years old | ≥65 years old |
|----------|-----------------------------|-----------------|--------------|
|          | All ages (n=363 558) | SUEA (n=2940) | All 18–64 years old (n=242 714) | SUEA (n=1900) | All ≥65 years old (n=95 189) | SUEA (n=983) |
| Blood eosinophil count, median (IQR) | 0.20 (0.11–0.35) | 0.40 (0.30–0.60) | 0.20 (0.12–0.34) | 0.40 (0.30–0.60) | 0.20 (0.10–0.30) | 0.40 (0.30–0.55) |
| Blood eosinophil count ≥0.3×10⁹/L, n (%) | 156 136 (42.9) | 2140 (0) | 103 298 (42.6) | 1900 (0) | 37 629 (39.5) | 983 (0) |
| Female patients, n (% of females) | 91 865 (39.4) | 1952 (100) | 63 086 (39.8) | 1269 (100) | 22 010 (35.5) | 650 (100) |
| Male patients, n (% of males) | 64 271 (49.3) | 988 (100) | 40 212 (47.8) | 631 (100) | 15 619 (60.5) | 333 (100) |
| % Predicted PEF Available data, n (%) | 91 865 (39.4) | 1952 (100) | 63 086 (39.8) | 1269 (100) | 22 010 (35.5) | 650 (100) |
| Mean daily SABA dosage, n (%)† | 0 74 637 (20.5) | 610 (20.7) | 46 517 (19.2) | 354 (18.6) | 25 475 (26.8) | 250 (25.4) |
| 1–200 | 148 727 (40.9) | 315 (10.7) | 102 914 (42.4) | 180 (9.5) | 31 601 (33.2) | 132 (13.4) |
| >400 | 72 073 (19.8) | 504 (17.1) | 47 377 (19.5) | 286 (15.1) | 19 035 (20.0) | 211 (21.5) |
| Asthma therapy: GINA step, n (%)‡ | 58 159 (16.0) | 0 | 43 676 (18.0) | 0 | 8723 (9.2) | 0 |
| Step 1 | 115 346 (31.7) | 0 | 77 732 (32.0) | 0 | 26 297 (27.6) | 0 |
| Step 3 | 64 271 (49.3) | 0 | 49 070 (20.2) | 40 (2.1) | 17 134 (17.9) | 17 (1.7) |
| Step 4 | 105 242 (2.9) | 0 | 488 (16.6) | 313 (16.5) | 5784 (61.8) | 168 (17.1) |
| Prescribed ICS during the baseline year, n (%) | 300 920 (82.8) | 196 640 (81.0) | 1900 (100) | 84 615 (88.9) | 983 (100) |
| Cumulative ICS dosage (µg/day), baseline year, median (IQR)† | 329 (132–658) | 1425 (1068–1697) | 301 (110–656) | 1421 (1068–1967) | 460 (230–874) | 1479 (1066–1967) |
| Last ICS dosage prescribed, per GINA classification, n (%)‡ | 62 638 (17.2) | 1900 (100) | 105 503 (43.5) | 26 297 (27.6) | 39 438 (41.4) | 35 (3.6) |
| No ICS prescribed | 159 858 (44.0) | 114 (3.9) | 69 839 (28.8) | 569 (29.9) | 39 438 (41.4) | 330 (33.6) |
| Medium ICS dosage | 107 207 (29.5) | 943 (32.1) | 69 839 (28.8) | 569 (29.9) | 39 438 (41.4) | 330 (33.6) |
| High ICS dosage | 33 855 (9.3) | 1883 (64.0) | 21 298 (8.8) | 1256 (66.1) | 12 083 (12.7) | 618 (62.9) |
| ≥1 prescription during baseline, n (%) | 3 (0) | 0 | 3 (0) | 0 | 3 (0) | 0 |
| Omalizumab | 21 436 (5.9) | 1001 (34.0) | 14 209 (5.9) | 743 (39.1) | 5092 (5.3) | 216 (22.0) |
| Theophylline | 6073 (1.7) | 397 (13.5) | 3333 (1.4) | 276 (14.5) | 2676 (2.8) | 116 (11.8) |
| Cumulative high-dosage ICS, n (%)‡ | 59 953 (16.5) | 2940 (100) | 34 463 (14.2) | 1900 (100) | 24 327 (25.6) | 983 (100) |
| Cumulative high-dosage ICS+LABA, n (%)‡ | 46 687 (12.8) | 2940 (100) | 27 526 (11.3) | 1900 (100) | 18 419 (19.3) | 983 (100) |
| Cumulative high-dosage ICS+LABA for 2 years, n (%)§ | 34 898 (9.6) | 2940 (100) | 20 336 (8.4) | 1900 (100) | 14 128 (14.8) | 983 (100) |
| Maintenance OCS, n (%)¶ | 10 522 (2.9) | 488 (16.6) | 4573 (1.9) | 313 (16.5) | 5784 (6.1) | 168 (17.1) |
| Asthma attacks, mean (SD) | 0.31 (0.76) | 2.89 (1.32) | 0.30 (0.74) | 2.93 (1.35) | 0.36 (0.84) | 2.80 (1.27) |
| Median (range) | 0 (0–15) | 2 (2–14) | 0 (0–15) | 3 (2–14) | 0 (0–14) | 2 (2–13) |
| 0 attacks, n (%) | 228 836 (79.4) | 0 | 193 674 (79.8) | 0 | 73 362 (77.1) | 0 |
| 1 attack, n (%) | 50 675 (13.9) | 0 | 33 621 (13.9) | 0 | 14 229 (14.9) | 0 |
| 2–3 attacks, n (%)** | 20 793 (5.7) | 2307 (78.5) | 13 415 (5.5) | 1464 (77.1) | 6434 (68.3) | 800 (81.4) |
| ≥4 attacks, n (%)*** | 3254 (0.9) | 633 (21.5) | 2004 (0.8) | 436 (22.9) | 1164 (1.2) | 183 (18.6) |
| Risk-domain asthma control, n (%) | 232 944 (64.1) | 244 (8.3) | 157 232 (64.8) | 151 (7.9) | 58 070 (61.0) | 90 (9.2) |
| Overall asthma control, n (%) | 149 349 (41.1) | 77 (2.6) | 100 694 (41.5) | 43 (2.3) | 36 490 (38.3) | 33 (3.4) |
| Cumulative high-dosage ICS+LABA and ≥2 attacks, n (%) | 8164 (2.2) | 2940 (100) | 5098 (2.1) | 1900 (100) | 2919 (3.1) | 983 (100) |

Continued
define SUEA, ranging from 3.8 (95% CI 3.7 to 4.0) for an eosinophils count of ≥0.2 × 10^9/L to 4.2 (95% CI 3.8 to 4.7) for a count of ≥0.5 × 10^9/L (online supplementary table S4).

For the 10,552 patients in the main study population who received maintenance OCS during the baseline year, the total mean costs, including medication costs, were £552, for a cost ratio of 2.3 (95% CI 2.4 to 2.6) relative to all patients with asthma (table 3).

**Patients ≥40 years old with concomitant COPD**

Demographics and baseline clinical characteristics of patients ≥40 years with asthma and concomitant COPD are described in the online supplementary table S5. The percentage of these patients who had SUEA (blood eosinophil count ≥0.3 × 10^9/L) was greater than in the main study population (1596/37 703 or 4.2% vs 0.8% (2940/363 558) in the main population) (online supplementary table S1).

The mean asthma-related HCRU and costs for the total population of patients with concomitant COPD were much higher than those for the main study population with asthma but without concomitant COPD (total mean costs of £530 vs £222, respectively). Patients with SUEA and concomitant COPD had total mean costs of £866. Thus, the cost ratio for patients ≥40 years old with SUEA and concomitant COPD versus patients ≥40 years with asthma and concomitant COPD was 3.8 (95% CI 3.7 to 4.0).

**Table 2** Continued

| Variable | All ages (n=63 558) | SUEA (n=2940) | 18–64 years old | SUEA (n=1206) | ≥65 years old | SUEA (n=893) |
|----------|-------------------|---------------|----------------|---------------|--------------|--------------|
| Cumulative high-dose ICS+LABA and ≥4 attacks, n (%) | 1569 (0.4) | 633 (21.5) | 1011 (0.4) | 436 (22.9) | 533 (0.6) | 183 (18.6) |

*All patients with SUEA included 14 children who were 5–11 years old and 43 adolescent patients 12–17 years old.

**Table 3** Mean asthma-related HCRU, associated direct costs (£2015 pounds sterling, £), and HCRU and cost ratios during the outcome year for patients with SUEA and those receiving maintenance oral corticosteroids compared with all patients with active asthma (including patients with SUEA) in the UK general population

| Asthma-related HCRU outcome | All patients (n=63 558/146 485*) | SUEA (n=2940/1206*) | HCRU and cost ratios (95% CI)† | ≥1 OCS maintenance (n=10 522/4140*) | HCRU and cost ratios (95% CI)† |
|-----------------------------|---------------------------------|--------------------|--------------------------------|-----------------------------------|--------------------------------|
| GP visit†                   | Number                           | Costs              | Number                           | Costs                            | Number                           | Costs                            |
|                             | 1.36 (1.57)                      | £30.8 (49.8)       | 2.67 (2.80)                      | £77.0 (107.5)                    | 2.5 (2.4 to 2.6)                 | £193.0 (243.1)                   |
|                             | £14.5 (0.0–42.4)                 | £44.0 (14.5–101.7) | –                                | £289.4 (14.5–58.5)               | –                                | £289.4 (14.5–58.5)               |
| Hospital-based specialist visit | Number                           | Costs              | Number                           | Costs                            | Number                           | Costs                            |
|                             | 0.04 (0.33)                      | £6.9 (52.2)        | 0.30 (0.96)                      | £46.7 (149.2)                    | 6.8 (6.0 to 7.7)                 | £39.4 (138.6)                    |
|                             | £0.01 (0.12)                     | £1.6 (18.8)        | £0.04 (0.25)                     | £6.6 (44.7)                      | 4.1 (3.2 to 5.3)                 | £5.5 (38.2)                      |
| Hospitalisation*            | Number                           | Costs              | Number                           | Costs                            | Number                           | Costs                            |
|                             | 0.01 (0.12)                      | £10.4 (194.7)      | 0.05 (0.38)                      | £78.7 (660.3)                    | 7.6 (4.7 to 11.6)                | £69.6 (653.5)                    |
|                             | £170.1 (218.2)                   | £645.4 (285.4)     | 3.8 (3.7 to 3.9)                 | £363.6 (338.6)                   | 0.04 (0.37)                      | £6.7 (5.0 to 8.9)                |
|                             | £87.8 (18.0–244.9)               | £595.3 (451.8–760.5) | –                                | £285.2 (111.4–527.0)             | –                                | £285.2 (111.4–527.0)             |
| Total costs*                | £222.0 (337.2)                   | £861.0 (811.9)     | 3.9 (3.7 to 4.1)                 | £552.1 (842.8)                   | 2.5 (2.4 to 2.6)                 | £552.1 (842.8)                   |
|                             | £125.6 (43.1–297.9)              | £707.0 (523.0–951.0) | –                                | £370.4 (159.6–689.7)             | –                                | £370.4 (159.6–689.7)             |

Data are reported as mean (SD) unless otherwise noted. The medians (IQRs) that are not included in the table were all 0 (0–0).

*The second number of patients in the column headers represents those in the Clinical Practice Research Datalink who had linked Hospital Episode Statistics (HES), used to determine hospitalisations and associated costs, as factored into total costs. The SUEA cohort with HES data included 26 (2.2%) patients <18 years old. 195% CI, based on 1000 bootstrap replicates.

†GP visits included consultations with primary care physicians and asthma nurses.

ED, emergency department; GP, general practice; HCRU, healthcare resource use; OCS, oral corticosteroids; SUEA, severe, uncontrolled eosinophilic asthma.

Kerkhof M, et al. Thorax 2018;73:116–124. doi:10.1136/thoraxjnl-2017-210531

121
years with asthma and concomitant COPD was 1.6 (95% CI 1.6 to 1.7) (online supplementary table S6).

**DISCUSSION**

We identified a total of 2940 patients, representing <1% of patients in a general UK asthma population without concomitant COPD, as having SUEA, which we defined as at least two asthma attacks in the year before a recorded high blood eosinophil count (≥0.3 × 10^9/L) while receiving treatment with high-dosage ICS plus LABA during the 2 consecutive years bracketing the eosinophil count. Sixty-six percent of the patients with SUEA were women. They were older on average (56 vs 49 years old), and they had more frequent comorbidities than other patients with asthma. Moreover, the individuals with SUEA had greater asthma-related disease burden, consulting their general practitioners for asthma twice as frequently, and visiting the hospital-based specialist clinics seven times as frequently as the general asthma population. During the outcome year after the eosinophil count, they presented substantially greater asthma-related HCRU and associated direct costs, four times greater than those for the main study population of patients with active asthma.

Costs for HCRU in the UK are relatively lower than in some other countries. Therefore, the absolute difference in total costs between patients with SUEA and all patients with asthma may be greater in countries with more expensive healthcare systems, such as the USA.41 In a recent US study, the total mean, annual asthma-related costs for 101 patients with severe, uncontrolled asthma and eosinophil count of ≥0.3 × 10^9/L were US$3030 (2013 US dollars), roughly four times greater than the analogous costs in our study.39 We found that asthma medications comprised approximately 75% of total mean costs incurred by patients in each of the SUEA and general asthma populations and, thus, were the largest category of asthma-related costs in this study, similar to findings in other studies of severe uncontrolled asthma in the USA and UK.5 6 36 A 2009 systematic review of 68 studies evaluating the economic burden of asthma identified medications or hospitalisations, depending on the study, as being the major drivers of asthma-related direct costs.6

We found greater asthma-related disease burden also in the subgroup of patients with concomitant COPD and elevated blood eosinophilis, as reported by others.37 The total mean asthma-related costs were similar for the two SUEA populations (those with and without concomitant COPD, £865 and £861, respectively). However, the cost ratio for those with SUEA and concomitant COPD was just 1.6 because of greater total mean costs (£530) for all patients with concomitant COPD, likely because they were older (all ≥40 years) and had more frequent comorbidities. Others have found that asthma-related healthcare costs for patients with asthma and concomitant COPD are nearly double those for matched patients with asthma without COPD.38

The subgroup of patients on maintenance OCS had mean total costs 2.5 times greater than those for the main study population.

Strengths of this study include the large general asthma population (>350 000 patients with active asthma) and the use of well-maintained databases of electronic medical records that are used frequently for observational research. We examined 1 baseline year, a standard interval used to clinically characterise patients, followed by 1 full outcome year to account for seasonal variation in asthma symptoms and considered a minimum interval for follow-up, as used in prior observational studies.11–13 33–39 Over 99% of patients in both main and SUEA populations had index dates after 1999, the year when the first fixed-dose combination ICS/LABA was introduced in the UK. Moreover, 91% of the main study population (and 94% of the SUEA population) had index dates in 2005 or later; therefore, most of the data were post-2004 and thus after the introduction on 1 April 2004 of the UK Quality Outcomes Framework (QOF) establishing incentives for improved data recording at GP practices.28 Indeed, smoking status, for example, was recorded for all but 2% of patients. Nonetheless, information on spirometry was limited, especially with regard to bronchodilator reversibility, which was available for only approximately 1% of patients. The datasets represent information collected for clinical and routine use rather than specifically for research purposes. Moreover, reports from hospital registries and referrals to chest physicians, in addition to eosinophil counts determined in hospital or the ED, may not have been consistently incorporated in patients’ general practitioner records. For this reason, we restricted the calculation of hospitalisations and associated costs to the subset of patients in the CPRD who were also included in the HES dataset.

Our choice of ≥0.3 × 10^9/L blood eosinophils as the primary definition of high blood eosinophil count is in line with prior reports that found eosinophil thresholds of 0.27 × 10^9/L and 0.26 × 10^9/L to be optimal for predicting sputum eosinophilia of ≥3%.9 10 31 Our definition of high-dosage ICS used in the SUEA definition was less than that defined as the high dosage in ERS/ATS guidelines defining severe asthma (ie, BDP ≥2000 µg/day for adults and ≥800 µg/day for children).8 However, the mean daily ICS dosages during the baseline and outcome years were calculated using all prescriptions averaged over 365 days (rather than a single prescribed dose) and thus represent total ICS exposure during the year.

Working retrospectively from databases limited our ability to separate severe treatment-resistant (refractory) asthma (ie, asthma that remains uncontrolled despite GINA Step 4/5 therapy) from difficult-to-control asthma (ie, uncontrolled asthma resulting from poor adherence, poor inhalation technique or treatable comorbidities, for example).8 In addition, our definition of asthma control was limited to items recorded in the database that reflected asthma control or lack thereof, such as acute OCS prescriptions; we were not able to assess asthma symptoms.

We included patients with SUEA in the main study population without concomitant COPD (as well as in the total population with concomitant COPD), because our aim was to report costs for a general asthma population, which, by definition, also includes patients with SUEA. Therefore, the main study and SUEA cohorts were not mutually exclusive, which caused a slight underestimation of the difference between cohorts. In post hoc calculations, the mean total costs for the main study population excluding SUEA were £216.7 (vs £222.0 when including SUEA), giving a cost ratio of 4.0, a difference of only 0.1 versus our reported ratio of 3.9.

Our general asthma population may not be fully representative of all patients with active asthma because we included only patients who had a recorded eosinophil count, limiting the generalisability of our findings. Eosinophil counts are usually performed for a reason, for example, for a health-related reason that may not be related to asthma. Indeed, previous studies report that patients with asthma and recorded eosinophil count tend to be older, more commonly female, and with greater asthma-related burden than the general asthma population.12 13 Finally, there are several other limitations of working retrospectively from databases. Because we restricted our analyses to HCRU with a primary code of asthma, it is possible that not all asthma-related direct costs were captured. Some
consultations for conditions occurring as a result of asthma treatment, for example, steroid-induced morbidity, or consultations not primarily related to asthma that involved discussion and management of asthma may not have been coded as being asthma-related. Moreover, when assigning costs, although most annual asthma reviews in the UK are performed by nurses, we could not be certain whether all asthma reviews were indeed done by nurses and all other consultations by primary care physicians. In addition, we could not assess indirect costs, such as lost school and work time, because these data are not included in patients’ medical records.

We note that patients with SUEA had fewer attacks in the outcome year compared with the baseline year (48% vs 100% with two or more attacks). This difference could be explained by regression to the mean. Alternatively, for some patients, perhaps their asthma was more aggressively or appropriately managed during the outcome year, or the natural history of severe asthma could include the transition to less severe asthma over time.

In conclusion, we found that 0.8% of patients in a general UK asthma population have SUEA, and 4.2% of those with asthma and concomitant COPD have SUEA, defined as having two or more asthma attacks in the year before a recorded high blood eosinophil count (≥0.3 × 10^9/L) and while under treatment for 2 years with high-dosage ICS plus LABA. Individuals who have SUEA despite treatment with high dosages of ICS combined with LABA therapy account for substantially greater asthma-related HCRU and associated direct costs than average patients with asthma.

Acknowledgements The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.

Contributors MK, TNT, SG, DG and DBP: participated in the conception and design of the study. MK and DBP: participated in the acquisition and analysis of the data. EVH: developed the first draft of the manuscript. All authors: participated in the interpretation of the data, the review and revision of the manuscript, and the approval to submit.

Funding This study was funded by AstraZeneca. All authors, including employees of the sponsor, participated in the development of the manuscript and had access to study data.

Competing interests MK is an employee of the Observational and Pragmatic Research Institute Pte Ltd (OPRI), which conducted this study with funding from AstraZeneca and which has conducted paid research in respiratory disease on behalf of the following other organizations: AERIAL Research and Development Ltd, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Theravance, UK National Health Service and Zenitiva. TNT, SG and DG are employees of AstraZeneca. JBS is a consultant to OPRI and has received pharmaceutical company grants from GSK in 2011 and Chiesi in 2012 via CIMERA his former home institution, and in 2014 and 2015 from Linde via Hospital Universitario de La Princesa; JBS participated in speaking activities, advisory committees and consultancies during the period 2011-2016 sponsored by: Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RIVL, Rovi, SEPAR, Takeda and Teva. EVH is a consultant to OPRI and has received fees for medical writing assistance from Merck, DBP has board membership with Aereon, AECO, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis and Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd from Aereon, AERIAL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Teva Pharmaceuticals, Theravance, UK National Health Service, Zenitiva; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, and Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from Aerocine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis and Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals and Zentiva; stock/stock options from AERIAL Research and Development Ltd which produces phytopharmaceuticals; owns Novartis, Pfizer, Respiratory Effective Group, Teva Pharmaceuticals, Theravance and Zenitiva; 74% of the social enterprise Optimum Patient Care Ltd (Australia, Singapore, and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme and Health Technology Assessment.

Ethics approval CPDR Independent Scientific Advisory Committee gave approval for use of the GPRD (ISAC registration number, 15_141) and the OPCRD is approved by the Health Research Authority of the UK NHS for clinical research use (REC reference: 15/EM/0150).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1 GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–62.
2 Global Initiative for Asthma (GINA). GINA Report, Global Strategy for Asthma Management and Prevention. http://ginasthma.org/ (accessed 11 Jul 2017).
3 Heekin PP, Wener RR, Amelkin M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015;135:896–902.
4 Zeiger RS, Schatz M, Dalal AA, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract 2016;4:120–9.
5 O’Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015;70:376–8.
6 Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24.
7 Heaney LG, Brightling CE, Menezes-Gow A, et al. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010;65:787–94.
8 ChungKF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–73.
9 Wagen AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum perisinus as surrogates for sputum eosinophils in asthma. Thorax 2015;70:115–20.
10 Zhang XY, Simpson JL, Powell H, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy 2014;44:1137–45.
11 Tran TN, Khattri DB, Ke X, et al. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol 2014;113:19–24.
12 Zeiger RS, Schatz M, Li Q, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract 2014;2:741–50.
13 Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015;3:849–58.
14 Denlinger LP, Phillips BR, Ramrattam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med 2017;195:302–13.
15 Blakey JD, Price DB, Pizicini E, et al. Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative. J Allergy Clin Immunol Pract 2017;5:1015–24.
16 Faddrow ID, Kom S, Howarth PH, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–9.
17 Ortega HG, Liu MC, Pirovano ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–207.
18 Castro M, Zangrilli J, Wedlischer MR, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355–66.
19 Sweeney J, Patterson CC, Menezes-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimun
Asthma

Patient Care Research Database and the British Thoracic Society Registry in Asthma.

20 FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128–41.

21 Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dose inhaled corticosteroids and long-acting β2-agonists (SIOCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115–27.

22 Fiocchi F, Lemière C, Beaufresne MF, et al. Development and validation of database indexes of asthma severity and control. Thorax 2007;62:581–7.

23 Clinical Practice Research Datalink. http://www.cprd.com/home/ (accessed 11 Jul 2017).

24 Boston Collaborative Drug Surveillance Program. The Clinical Practice Research Datalink. http://www.bu.edu/bcbspi/gpdata/ (accessed 11 Jul 2017);http://optimumpatientcare.org/cprd/ (accessed 11 Jul 2017).

25 Optimum Patient Care Research Database (OPCRD). http://optimumpatientcare.org/database-overview/ (accessed 8 Sep 2017)

26 UK National Health Service. Hospital Episode Statistics (HES). http://content.digital.nhs.uk/ (accessed 11 Jul 2017).

27 Roche N, Reddel H, Martin R, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc 2014;11(Suppl 2):S99–104.

28 UK National Health Service. Quality and Outcomes Framework (QOF). http://www.hscic.gov.uk/qof (accessed 11 Jul 2017).

29 British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. A national clinical guideline. 2014 https://www.brit-thoracic.org.uk/document-library-clinical-information/asthma/britgsign-asthma-guideline-2014/ (accessed 11 Jul 2017).

30 Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society-European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59–99.

31 Arron JR, Izuahara K. Asthma biomarkers: what constitutes a ‘gold standard’? Thorax 2015;70:105–7.

32 Enhancing the QUALity and Transparency Of Health Research (EQUATOR) Network. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. https://www.equator-network.org/reporting-guidelines/cheers/ (accessed 11 Jul 2017).

33 Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013;346:f1049.

34 Drummond MF, Jefferson TD. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275–83.

35 Martin RJ, Price D, Roche N, et al. Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study. NPJ Prim Care Respir Med 2014;24:14081.

36 Zeiger RS, Schatz M, Dalal AA, et al. Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study. J Allergy Clin Immunol Pract 2017;5:144–53.

37 Zeiger RS, Schatz M, Li Q, et al. Characteristics and outcomes of HEDIS-defined asthma patients with COPD diagnostic coding. J Allergy Clin Immunol Pract 2016;4:273–83.

38 Gerhardsson de Verdier M, Andersson M, Kern DM, et al. Asthma and chronic obstructive pulmonary disease overlap syndrome: doubled costs compared with patients with asthma alone. Value Health 2015;18:759–66.

39 Suissa S, Ernst P, Kozouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002;57:880–4.

40 NHS National Services Scotland, Information Services Division. Health conditions general practice: Asthma. http://www.isdscotland.org/Health-Topics/General-Practice/GP-consultations/Health-Conditions/Asthma/index.asp (accessed 29 Jul 2017).

41 Barrett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005;34:215–20.

42 Chen W, Marra CA, Lynd LD, et al. The natural history of severe asthma and influences of early risk factors: a population-based cohort study. Thorax 2016;71:267–75.